My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

AbbVie (NY:ABBV)

214.35 -0.67 (-0.31%)

Official Closing Price Updated: 7:00 PM EST, Jan 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

92 93 Next >

AbbVie Options Trading: A Deep Dive into Market Sentiment ↗

August 29, 2024

Via Benzinga

Biotech And Life Science Sector Update Summer Of 2024 ↗

August 29, 2024

It’s the slowest week of the year, we are at the market top and most earnings reports are good.

Via Talk Markets

Bull Market Buys: 3 Dividend Stocks to Own for the Long Run ↗

August 29, 2024

There are three operative words with these dividend stocks: buy and hold.

Via The Motley Fool

As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors ↗

August 28, 2024

Neurocrine Biosciences reports Phase 2 trial results for NBI-1117568 showing significant improvement in schizophrenia symptoms, with an 18.2-point reduction in PANSS scores at a 20 mg dose.

Via Benzinga

Neurocrine Bio Dives As Schizophrenia Trial Results Lags Peers ↗

August 28, 2024

As new schizophrenia drugs move toward approval, Neurocrine Biosciences reports a subpar outcome for its phase 2 trial.

Via Investor's Business Daily

3 Best Growth Stocks to Own for the Next 10 Years

August 28, 2024

When in doubt, zoom out; these three growth stocks have a history of strong performance that is likely to continue for the next 10 years

Via MarketBeat

Topics Economy

AbbVie Unusual Options Activity For August 26 ↗

August 26, 2024

Via Benzinga

Key Takeaways From AbbVie Analyst Ratings ↗

August 23, 2024

Via Benzinga

Prediction: Eli Lilly's Latest Move Will Threaten AbbVie Stock ↗

August 28, 2024

It'll be a while before there's any impact, but it could be a big deal.

Via The Motley Fool

Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna ↗

August 27, 2024

Drug companies are investing in schizophrenia treatments as patients are desperate for a drug that has few side effects, Bloomberg reports.

Via Benzinga

Donald Trump Owns These 21 Dividend Kings. Should You? ↗

August 26, 2024

Some of Trump's Dividend Kings deserve a crown more than others.

Via The Motley Fool

Topics Government

3 Unstoppable Dividend Stocks to Buy Right Now ↗

August 25, 2024

These stocks are the A-team for income investors.

Via The Motley Fool

Unpacking the Latest Options Trading Trends in AbbVie ↗

August 20, 2024

Via Benzinga

$100 Invested In This Stock 10 Years Ago Would Be Worth $400 Today ↗

August 20, 2024

Via Benzinga

Decoding AbbVie's Options Activity: What's the Big Picture? ↗

August 14, 2024

Via Benzinga

Botox Innovator Revance Therapeutics Goes Private In Over $900M Deal ↗

August 12, 2024

Crown Laboratories will acquire Revance Therapeutics for $924 million, paying $6.66 per share — a premium of 89%.

Via Benzinga

Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets ↗

August 23, 2024

Analysts expect Novo Nordisk's Ozempic and other major drugs to be included in 2027 Medicare price negotiations. Despite concerns, experts predict limited financial impact on companies like Pfizer,...

Via Benzinga

How To Build A Dividend Growth Portfolio In An Overpriced Market ↗

August 22, 2024

The stock market as measured by the S&P is currently at an all-time high which makes it very challenging to try to build a quality dividend growth portfolio.

Via Talk Markets

Topics Stocks

Biotech Bull Market: 3 Ways To Play It ↗

August 20, 2024

Although we are in the later stages of this bull market a cut in interest rates by the Fed should help biotech as you have seen from the recent rally.

Via Talk Markets

Topics Economy

3 High-Yield Stocks to Buy Now That Have Increased Their Dividends for 25 Years or More ↗

August 18, 2024

These stocks dividends continue to flow and grow.

Via The Motley Fool

These 3 Healthcare Companies Had the Top-Selling Drugs Last Year ↗

August 18, 2024

This list of top-selling drugs could look drastically different in a few years.

Via The Motley Fool

3 High-Yielding Dividend Growth Stocks That Retirees Can Rely On for Recurring Income ↗

August 17, 2024

These stocks all pay more than 3%, and they have been regularly increasing their payouts in recent years.

Via The Motley Fool

Lock in Gains: 3 Dividend Stocks Poised to Boost Payouts Soon

August 16, 2024

These three stocks have a long history of increasing their dividends and are likely to benefit from sector rotation on expectations of lower interest rates

Via MarketBeat

Topics Artificial Intelligence Economy

10 Health Care Stocks With Whale Alerts In Today's Session ↗

August 15, 2024

Via Benzinga

The 3 Best Stocks to Buy to Survive Another S&P 500 Crash ↗

August 15, 2024

These three stocks to buy now will protect your portfolio if the S&P 500 crashes again regardless of whether there is a recession or not.

Via InvestorPlace

Topics Economy Stocks

Cancer-Focused Syros Pharmaceuticals Stops Mid-Stage Leukemia Combo Therapy Study, Cites Disappointing Unexpected Outcome ↗

August 13, 2024

Syros Pharmaceuticals announces discontinuing enrollment in the SELECT-AML-1 Phase 2 trial due to the low probability of demonstrating superiority. The trial evaluated tamibarotene with venetoclax and...

Via Benzinga

3 Stocks Retirees Should Absolutely Love ↗

August 10, 2024

All of these stocks can provide steady income to retired investors.

Via The Motley Fool

As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032

August 09, 2024

EQNX::TICKER_START (NYSE:OGEN),(NYSE:ABT),(NASDAQ:BIIB),(NYSE:PFE),(NYSE:ABBV) EQNX::TICKER_END

Via FinancialNewsMedia

The Defensive Sectors And VIX Have NOT Given The All-Clear Signal ↗

August 08, 2024

The market has been a rollercoaster lately, with the resilience of defensive sectors and the modest bounce in the technology sector painting an intriguing picture.

Via Talk Markets

Topics Stocks

Warren Buffett's Approach To Investing In Election Years ↗

August 07, 2024

Warren Buffett, known as the 'Oracle of Omaha', is a highly successful American investor who manages his portfolio consistently, regardless of elections or market conditions.

Via Benzinga

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

92 93 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.